Scarica l'app Stockscreener
22.52
4.55%
0.98
Precedente Chiudi:
$21.54
Aprire:
$22
Volume 24 ore:
1.19M
Relative Volume:
0.61
Capitalizzazione di mercato:
$2.48B
Reddito:
$12.59M
Utile/perdita netta:
$-212.39M
Rapporto P/E:
-7.2991
EPS:
-3.0853
Flusso di cassa netto:
$-185.92M
1 W Prestazione:
+1.72%
1M Prestazione:
-14.73%
6M Prestazione:
+129.80%
1 anno Prestazione:
+150.78%
Intervallo 1D:
$21.62
$22.81
Intervallo di 1 settimana:
$21.20
$22.81
Portata 52W:
$5.1501
$27.65
Immunome Inc Stock (IMNM) Company Profile
Nome
Immunome Inc
Settore
Industria
Telefono
610-321-3700
Indirizzo
18702 N. CREEK PARKWAY, BOTHELL
Compare IMNM vs VRTX, REGN, ARGX, ALNY, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
IMNM
Immunome Inc
|
22.52 | 2.38B | 12.59M | -212.39M | -185.92M | -3.0853 |
|
VRTX
Vertex Pharmaceuticals Inc
|
477.89 | 120.48B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
787.50 | 81.05B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
749.56 | 46.33B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
327.30 | 42.26B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
299.02 | 32.87B | 5.36B | 287.73M | 924.18M | 2.5229 |
Immunome Inc Stock (IMNM) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-02-12 | Iniziato | H.C. Wainwright | Buy |
| 2025-12-01 | Iniziato | Truist | Buy |
| 2025-09-22 | Iniziato | Goldman | Buy |
| 2025-09-05 | Iniziato | Craig Hallum | Buy |
| 2025-04-02 | Iniziato | Lake Street | Buy |
| 2024-11-08 | Iniziato | Stephens | Overweight |
| 2024-05-31 | Iniziato | Piper Sandler | Overweight |
| 2024-04-30 | Iniziato | JP Morgan | Overweight |
| 2024-04-15 | Iniziato | Guggenheim | Buy |
| 2024-01-29 | Iniziato | Leerink Partners | Outperform |
| 2023-12-19 | Iniziato | Wedbush | Outperform |
| 2021-10-29 | Iniziato | Cantor Fitzgerald | Overweight |
Mostra tutto
Immunome Inc Borsa (IMNM) Ultime notizie
Immunome (IMNM) TTM Net Loss Of US$212 Million Reinforces Bearish Profitability Narratives - simplywall.st
Investment Manager Fully Exits Immunome Stock in $37.3 Million Sale, According to Latest SEC Filing - AOL.com
IMNM: Stephens & Co. Lowers Price Target to $30, Maintains Overw - GuruFocus
Immunome (IMNM): Craig-Hallum Raises Price Target to $36.00 and - GuruFocus
Immunome (NASDAQ:IMNM) Price Target Raised to $36.00 - MarketBeat
Stephens Cuts Immunome (NASDAQ:IMNM) Price Target to $30.00 - MarketBeat
Decoding Immunome Inc (IMNM): A Strategic SWOT Insight - GuruFocus
Immunome (IMNM) Reports Wider Losses and Revenue Decline - GuruFocus
Immunome 2025 Net Loss Narrows - marketscreener.com
Immunome (IMNM) Projects Strong Cash Position and Promising Drug Developments - GuruFocus
Earnings Flash (IMNM) Immunome Posts Full Year 2025 Loss $2.43, vs. FactSet Est of $2.24 Loss - marketscreener.com
Immunome: Q4 Earnings Insights - Benzinga
IMNM: Net loss improved to $212.4M in 2025, with $653.5M cash supporting late-stage oncology pipeline - TradingView
Immunome (IMNM) 2025 10-K: Phase 3 varegacestat data and ADC pipeline - Stock Titan
Immunome (IMNM) posts 2025 loss but scores major Phase 3 cancer win - Stock Titan
Immunome Reports Full Year 2025 Financial Results and Provides Business Update - Business Wire
TD Asset Management Inc Purchases 95,750 Shares of Immunome, Inc. $IMNM - MarketBeat
IMNM Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
How Immunome’s Oncology Pivot and Varegacestat NDA Push Could Impact Immunome (IMNM) Investors - simplywall.st
Immunome, Inc. (IMNM) Sets Sights on $1B Opportunity amid Pipeline Development - Insider Monkey
11 Best Cancer Stocks to Invest In Now - Insider Monkey
Immunome, Inc. (IMNM) Investor Outlook: Exploring a Promising 60% Upside in the Biotech Sector - DirectorsTalk Interviews
Private Capital Advisors Inc. Has $1.38 Million Stake in Immunome, Inc. $IMNM - MarketBeat
Assessing Immunome (IMNM) Valuation After Recent Share Price Pullback - Yahoo Finance
Immunome to Present at Upcoming March 2026 Investor Conferences - BioSpace
First Week of October 16th Options Trading For Immunome (IMNM) - Nasdaq
Immunome to Present at Upcoming Investor Conferences - The Joplin Globe
Biotech-Focused Fund Adds $12 Million to Immunome Bet as Stock Surges 120% - Yahoo Finance
Risk Analysis: Is Immunome Inc part of any ETF2025 Year in Review & Technical Pattern Based Signals - baoquankhu1.vn
Immunome, Inc. $IMNM Shares Acquired by NEOS Investment Management LLC - MarketBeat
Immunome, Inc. (IMNM) - DirectorsTalk Interviews
Market Fear: Can Immunome Inc be the next market leaderShort Setup & Weekly Breakout Watchlists - baoquankhu1.vn
Is Immunome, Inc. (IMNM) the best booming stock to buy right now? - MSN
Jim Cramer on Immunome: "If you want to speculate on it, fine" - MSN
Should You Buy Immunome Inc (IMNM) Today? Analysis, Price Targets, and 2026 Outlook. - Intellectia AI
Redmile Group (IMNM) discloses 5.2% Immunome stake via managed funds - Stock Titan
Brokers Issue Forecasts for Immunome FY2025 Earnings - MarketBeat
Trading Systems Reacting to (IMNM) Volatility - Stock Traders Daily
Immunome CEO Touts Phase 3 Desmoid Win, Near-Term FDA NDA Plan and Early IM-1021 ADC Responses - MarketBeat
Immunome (NASDAQ:IMNM) Stock Rating Upgraded by HC Wainwright - MarketBeat
Institutional investors in Immunome, Inc. (NASDAQ:IMNM) see US$269m decrease in market cap last week, although long-term gains have benefitted them. - Yahoo Finance
H.C. Wainwright initiates coverage on Immunome stock with Buy rating By Investing.com - Investing.com South Africa
H.C. Wainwright initiates coverage on Immunome stock with Buy rating - Investing.com Australia
How do insiders feel about Immunome Inc.Market Growth Summary & Daily Stock Trend Reports - mfd.ru
HC Wainwright Initiates Immunome at Buy With $40 Price Target - marketscreener.com
Immunome (IMNM) Initiates Coverage with a Buy Rating by HC Wainw - GuruFocus
This Sezzle Analyst Begins Coverage On A Bullish Note; Here Are Top 3 Initiations For Thursday - Sahm
Immunome (IMNM): Biotech minnow in the spotlight as volatility returns to cancer drug hunters - AD HOC NEWS
Principal Financial Group Inc. Buys 762,147 Shares of Immunome, Inc. $IMNM - MarketBeat
Candriam S.C.A. Buys 541,441 Shares of Immunome, Inc. $IMNM - MarketBeat
Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)February 5, 2026 - BioSpace
Immunome Inc Azioni (IMNM) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.11%
6.00%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):